1. Radiation Therapy for Heterotopic Ossification: A Systematic Review.
- Author
-
Bang C, Jutkowitz E, Caputo E, Yan SX, Mai HJ, Kanaan G, Leonard T, Rickard T, Trikalinos T, Rudolph JL, and Rieke K
- Abstract
Purpose: Heterotopic ossification (HO) is a benign disorder characterized by ectopic bone formation in soft tissues that can lead to functional loss in patients. We conducted a systematic review of the evidence on the use of radiation therapy (RT) for the prevention or treatment of HO., Methods and Materials: Literature searches were conducted using Medline (via PubMed), Embase, and ClinicalTrials.gov until April 1
, 2023. Medical subject headings and free text terms relevant to HO and RT were used. In brief, eligible study participants were ≥18 years of age with HO and were treated with low-dose external RT. Two reviewers screened relevant abstracts and extracted full-text data for analysis. The review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines., Results: Ten studies evaluating the effect of RT for either the prevention or treatment of HO met the inclusion for evidence synthesis. Nine randomized controlled trials did not clearly report their methods and had a medium risk of bias. The studies were conducted between 1988 and 2008, with follow-up ranging on average from 3 to 59 months posttreatment. A total of 1530 participants were analyzed, and 566 were treated with RT following fracture fixation, total hip arthroplasty, or total hip replacement. In pooled data from 8 randomized controlled trials, there was a nonsignificant but clinically meaningful reduction in the presence of HO at follow-up for patients who received RT versus comparators (pooled odds ratio, 0.47; 95% CI, 0.19, 1.17). There was minimal evidence of adverse events., Conclusions: This systematic review found a clinically, but not statistically, significant benefit of prophylactic RT for HO at follow-up. These findings are tempered by a moderate risk of bias. While practice patterns vary, RT for HO prophylaxis in high-risk patients may have benefits that outweigh the risks., Competing Interests: Disclosures Christine Bang has received support for meeting attendance or travel from the VA National Oncology Program and the Baltimore VA; Eric Jutkowitz, Taylor Rickard, Thomas Trikalinos, Katherine Rieke, and James L. Rudolph were supported by the VA's Evidence Synthesis Program; Tayler Leonard was supported by the Summer Undergraduate Research Fellowship, and then Summer Research Early Identification Program and Brown University; Sherry X. Yan is a member of the Membership Committee of the Massachusetts Society of Clinical Oncologists, and the Government Relations Council for the American Society of Radiation Oncology; James L. Rudolph has received grants or contracts from the VA, NIA, Brown Physicians, Lifespan Health System, and Icosavax; Katherine Rieke was previously employed by the American Academy of Dermatology; Eduardo Caputo, Htun Ja Mai, and Ghid Kanaan have no conflicts to disclose. This report was prepared by the Evidence Synthesis Program Center located at the VA Providence Health Care System, directed by Eric Jutkowitz, PhD and James Rudolph, MD and funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development. The findings and conclusions in this document are those of the author(s) who are responsible for its contents and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs., (Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF